4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $36.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 227.57% from the company’s current price.

A number of other research analysts also recently weighed in on FDMT. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research report on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $10.99 on Monday. The company has a market capitalization of $574.56 million, a PE ratio of -4.28 and a beta of 2.70. 4D Molecular Therapeutics has a 12-month low of $4.14 and a 12-month high of $14.00. The firm’s fifty day moving average is $10.36 and its 200 day moving average is $9.45.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. Sell-side analysts expect that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

Insider Activity

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. This represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 184,811 shares of company stock worth $2,075,906. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of the stock. RA Capital Management L.P. grew its holdings in 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the period. Janus Henderson Group PLC raised its stake in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after buying an additional 174,489 shares during the period. State Street Corp lifted its position in shares of 4D Molecular Therapeutics by 197.5% during the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of 4D Molecular Therapeutics by 76.6% during the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock worth $14,520,000 after acquiring an additional 840,000 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.